Not for External Distribution
Extremely Private & Confidential – Internal Circulation Only
Summary
MEDTRAC™ has identified a novel remote biofeedback-based monitoring method that materially extends the company’s existing testing capabilities. Initial internal testing conducted today produced highly concordant results, warranting controlled clinic validation before any external communication. The R-SCAN can be paired with HRV wearable devices (for greater correlation) or used remotely on its own.
The Key aspect of this discovery is that it can be conducted remotely and possibly without DNA.
This notice documents the discovery for internal awareness only.
Mockup Images provide an illustration.
INTERNAL PRESS RELEASE – ON HOLD
(Draft for internal review – not approved for publication)
MEDTRAC™ Identifies Novel Remote Biofeedback Method for Continuous Health State Monitoring
Malta – 1 February 2026
MEDTRAC™ today confirmed the internal identification of a previously unrecognised remote biofeedback data acquisition and analysis method that removes the need for any weaable on adhacent device, representing one of the most strategically significant technical discoveries in the company’s history.
The method enables remote capture and interpretation of regulatory biofeedback signals, which—when combined with MEDTRAC’s established local Grade Scan methodology—creates a multi-layered, longitudinal view of system load, regulatory balance, and health-state dynamics.
This combined model moves MEDTRAC beyond static, point-in-time assessments toward continuous or near-continuous system state monitoring, with data refresh cycles configurable from hourly to daily. We will carry out further inteneeal testing to validate this finding.
A New Class of Remote Screening & Monitoring Capability
Unlike conventional remote health tools that rely primarily on questionnaires or limited biometric proxies, this approach captures complex response-pattern data remotely without any device, enabling:
- Continuous tracking of stress, recovery, and regulatory load
- Longitudinal assessment of pathogen and system burden trends
- High-resolution visualisation of health-state trajectories
- Objective monitoring of change during recovery or intervention phases
When paired with locally performed Grade Scans (clinic or supervised home use), the system forms an alternative to our existing complementary testing tools and strethens the remote only service. This bridges in-person precision with remote scalability.
Ultra-Low-Cost, High-Scalability Architecture
A core strength of the discovery is its exceptionally low projected hardware cost, with anticipated public unit costs below USD $100 at scale.
This enables:
- Affordable, ongoing monitoring for individuals
- Population-scale research and cohort deployment
- Reduced dependency on repeated clinic visits
- Accessibility in low-resource and geographically distributed settings
The architecture supports monitoring and feedback intelligence, with therapeutic use cases treated as a separate downstream application layer, subject to regulatory and governance controls.
Early Validation & Development Path
- Initial proof-of-concept testing completed using AI-assisted analysis without dedicated software automation whihc will be needed for testing, as its too timeconsuming to be done manually.
- Early results have exceeded internal expectations
- No public claims or external validation asserted at this stage
Next phase:
- Controlled clinic validation
- Expanded AI-assisted analysis of data provided
- Automated proof-of-concept software development
- Research-grade visualisation and dashboards to be develoepd
- Integration into Longevity Trust led and research programmes
- Focus on Animal health monitoring to build reliable data
Strategic Significance
This discovery could be a cornerstone in MEDTRAC’s transition from a clinic-centric model to a platform-led, clinic-enabled ecosystem, where:
- Clients may engage remotely or via partner clinics
- Clinics retain responsibility for face-to-face care
- MEDTRAC™ provides clinical intelligence, monitoring, and analytics
- Foundations and research partners support development and deployment
Global scale is achieved without compromising clinical integrity or governance.
About MEDTRAC™
MEDTRAC™ develops advanced health intelligence systems combining biofeedback, systems analysis, and AI-driven visualisation to support clinicians, researchers, and structured health programmes.
IMPORTANT NOTICE
This document is strictly internal. It must not be shared externally or referenced publicly without written approval from Aurvantis Group Directors and review by legal and regulatory counsel.
MEDTRAC is part of the Aurvantis Group
Leave a Reply